


Fimasartan-d₆

Cat. No.:	HY-B0780S
Molecular Formula:	C ₂₇ H ₂₅ D ₆ N ₇ OS
Molecular Weight:	507.68
Target:	Apoptosis; Angiotensin Receptor; Isotope-Labeled Compounds
Pathway:	Apoptosis; GPCR/G Protein; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Fimasartan-d ₆ is deuterium labeled Fimasartan.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Chi YH, et al. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. *Biol Pharm Bull*. 2013;36(7):1208-15.
- [3]. Lee HW, et al. Effect of age on the pharmacokinetics of fimasartan (BR-A-657). *Expert Opin Drug Metab Toxicol*. 2011 Nov;7(11):1337-44.
- [4]. Ryu S, et al. Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. *Biol Pharm Bull*. 2013;36(3):467-74.
- [5]. Shin KH, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. *J Cardiovasc Pharmacol*. 2011 Nov;58(5):492-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA